Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of polypeptide as olfactory receptor Olfr109 antagonist ligand

A ligand and carrier technology, applied in the field of anti-metabolic disease drugs, can solve problems such as gastrointestinal discomfort, and achieve good specificity and cost-effective effects

Active Publication Date: 2020-11-13
SHANDONG UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, commonly used hypoglycemic drugs in clinic, such as biguanides, thiazolidinediones and sulfonylureas, etc., although the short-term efficacy is significant, but long-term use is usually accompanied by a variety of side effects, such as gastrointestinal discomfort and osteoporosis, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polypeptide as olfactory receptor Olfr109 antagonist ligand
  • Application of polypeptide as olfactory receptor Olfr109 antagonist ligand
  • Application of polypeptide as olfactory receptor Olfr109 antagonist ligand

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Polypeptide specifically antagonizes Olfr109 downstream signaling pathway and inhibits Olfr109 function Experimental steps:

[0035] 1. Use 431A peptide synthesizer (Perkin Elmer) to synthesize the following polypeptides:

[0036] Arg-Phe-Val-Ala-Ile-Cys-Ser-Pro-Leu-Arg-Tyr-Thr-Ala-Ile-Met

[0037] 2. Using molecular biology methods, construct the Olfr109 recombinant plasmid with genetic recombination, overexpress Olfr109 with HEK293 cells, use the Glosensor method to detect the principle of the second messenger cAMP, and stimulate the cells to produce cAMP with Forskolin, an agonist of adenylate cyclase At the same time, the agonist InsB of Olfr109 was given to stimulate the concentration of intracellular cAMP to characterize the activation of the Gi signaling pathway downstream of Olfr109. On this basis, the polypeptide antagonist was given to characterize the degree of recovery of intracellular cAMP concentration. The antagonism of the Gi signaling pathway...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of anti-metabolic disease drugs, and particularly relates to application of polypeptide as an olfactory receptor Olrfr109 antagonist ligand. Existing researches show that the olfactory receptor Olfr109 plays an important role in maintaining the steady state of blood glucose and also has an influence on the insulin secretion level. The invention providesan antagonist ligand aiming at an olfactory receptor Olfr109 according to the research background. The polypeptide can inhibit downstream Gi through combination with Olfr109, and inhibit downstream Gi, beta-arrestin1 signal channel and a beta-arrestin2 signal channel through combination with Olfr109, and the can be used for preparing metabolic disease model drugs. The antagonist has the functionsof relieving insulin secretion disorders caused by excessive activation of the Olfr109 and promoting insulin secretion, and has popularization significance as a good clinical drug or research tool.

Description

technical field [0001] The disclosure belongs to the technical field of anti-metabolic disease drugs, and specifically relates to the application of a polypeptide as an olfactory receptor Olfr109 antagonist ligand and Gi, β-arrestin-1 and β-arrestin-2 signal pathway inhibitors. Background technique [0002] The information disclosed in this Background section is only intended to increase the understanding of the general background of the disclosure, and is not necessarily to be taken as an acknowledgment or any form of suggestion that the information constitutes prior art that is already known to those skilled in the art. [0003] Diabetes mellitus is a metabolic disease characterized by elevated blood sugar. Insufficient insulin secretion or insulin resistance is a key factor in the occurrence of diabetes. Currently commonly used hypoglycemic drugs in clinical practice, such as biguanides, thiazolidinediones, and sulfonylureas, have significant short-term efficacy, but long...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08C12N15/11A61K38/10A61P3/04A61P3/10
CPCC07K7/08A61P3/04A61P3/10A61K38/00
Inventor 孙金鹏于晓程杰杨照
Owner SHANDONG UNIV
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com